Healtheuniverse Inc. (PINKSHEETS: HLUN), a diversified biotechnology development firm specializing in the development and commercialization of patented biopharmaceutical and biomedical products, announced today that phase one international research efforts are focused on being the first to commercialize stem cell applications in the $15 billion worldwide plastic surgery and cosmetic surgery market. The Company intends to sell its proprietary technology through packaged products and licensing agreements, once human clinical trials are completed, to plastic, reconstructive, and cosmetic surgeons as a simple way for the industry to utilize our proprietary technology worldwide.
